Bio-Rad Laboratories

{{Infobox company

| name = Bio-Rad Laboratories, Inc.

| logo = Bio-Rad Laboratories Logo.svg

| image = Bio-Rad-along-the-Bay.jpg

| image_caption = Bio-Rad Laboratories is based in Hercules, California, located along the Bay.

| type = Public

| traded_as = {{ubl|{{NYSE|BIO}} (Class A)|S&P 400 component}}

| founders = {{unbulleted list|David Schwartz|Alice Schwartz}}

| area_served = Global

| key_people = {{unbulleted list|Norman Schwartz |(President & CEO)|Jonathan DiVincenzo |(COO)||Roop Lakkaraju |(CFO){{cite news|url=https://blogs.wsj.com/cfo/2019/04/03/cfo-moves-alcon-bio-rad-laboratories-cmc-markets/|title=CFO Moves: Alcon, Bio-Rad Laboratories, CMC Markets|newspaper=The Wall Street Journal|date=3 April 2019|accessdate =Nov 19, 2019|last1=Shumsky|first1=Tatyana}}|Michael Crowley |(EVP Global Commercial Operations)|James Barry{{cite web|url=https://www.biospace.com/article/releases/bio-rad-appoints-simon-may-executive-vice-president-and-life-science-group-president/|title=Bio-Rad Appoints Simon May Executive Vice President and Life Science Group President|publisher=biospace.com |accessdate=26 December 2021}} |(President, Life Science Group)|Eva Engelhardt |{{nowrap|(President, Clinical Diagnostics Group)}}}}

| industry = {{ubl|Medical laboratories|life science research}}

| genre =

| products =

| services =

| revenue = {{decrease}} {{US$|2.57 billion|link=yes}} (2024)

| operating_income = {{decrease}} {{US$|269 million}} (2024)

| net_income = {{decrease}} {{US$|-1.8 billion}} (2024)

| assets = {{decrease}} {{US$|9.36 billion}} (2024)

| equity = {{decrease}} {{US$|6.57 billion}} (2024)

| num_employees = 7,700 (2024)

| parent =

| subsid =

| website = {{URL|bio-rad.com}}

| founded = {{Start date and age|1952}}

| hq_location_city = Hercules, California

| hq_location_country = U.S.

| caption =

| footnotes = {{Cite web |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/12208/000001220825000007/bio-20241231.htm |title=2024 Annual Report (Form 10-K) |date=February 14, 2025 |publisher=U.S. Securities and Exchange Commission}}

}}

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide.

Business segments

Bio-Rad’s life science products primarily include instruments, software, consumables, reagents, and content for the areas of cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education. These products are based on technologies to separate, purify, identify, analyze, and amplify biological materials such as antibodies, proteins, nucleic acids, cells, and bacteria.Bio-Rad Annual Report 2016 | http://www.bio-rad.com/webroot/web/pdf/corporate/annualreport/Annual_Report_2016.pdf

Bio-Rad’s diagnostic products and systems use a range of technologies and provide clinical information in the blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets. These products are used to support the diagnosis, monitoring, and treatment of diseases and other medical conditions.{{cite web|url=https://www.360dx.com/hematologycoagulation/bio-rad-plans-additional-instruments-burgeoning-blood-typing-business |title=Bio-Rad Plans Additional Instruments for Burgeoning Blood Typing Business |date=8 March 2018 |publisher=360dx.com |accessdate=21 January 2022}}

History

Bio-Rad Laboratories was founded in 1952 by David Schwartz and his wife Alice, both recent graduates of the University of California, Berkeley.{{cite web|url=https://www.forbes.com/profile/alice-schwartz/ |title=Alice Schwartz |work=forbes.com |accessdate=21 January 2022}} In 1976, Bio-Rad acquired Environmental Chemical Specialties (ECS), a producer of human control serum.{{cite web|url=https://pdf.zlibcdn.com/dtoken/e43c9f8539295662d092754b5ff063da/ac60364a730.pdf |title=ANALYTICAL CHEMISTRY, VOL. 47, NO. 14, DECEMBER 1975 |publisher=pdf.zlibcdn.com |accessdate=21 January 2022}}{{cite web|url=https://www.bio-rad.com/en-us/corporate/our-history?ID=MR8ISY4VY |title=Our history |publisher=bio-rad.com |accessdate=21 January 2022}}

In 2008, Bio-Rad were notable for being the opening bell ringers at the New York Stock Exchange on 24 October, a date which went down in financial history as 'Bloody Friday', which saw many of the world's stock exchanges experience the worst declines in their history, with drops of around 10% in most indices.KUMAR, V. PHANI (October 24, 2008). "[https://www.marketwatch.com/story/indexes-fall-hard-on-bloody-friday Indexes fall hard on bloody Friday]". Marketwatch.

In 2011, Bio-Rad acquired a new technology, droplet digital PCR. Droplet digital PCR allows scientists to distinguish rare sequences in tumors and precisely measure copy number variation.Bio-Rad Annual Report 2011

In January 2013, Bio-Rad purchased AbD Serotec, a division of MorphoSys AG.{{cite web|last1=Mark |first1=Barry |title=Revenue Update on Bio-Rad Laboratories, Inc. |url=http://www.marketsbureau.com/revenue-update-on-bio-rad-laboratories-inc/319298/ |website=Markets Bureau |accessdate=4 March 2015 |url-status=usurped |archiveurl=https://web.archive.org/web/20150402145613/http://www.marketsbureau.com/revenue-update-on-bio-rad-laboratories-inc/319298/ |archivedate=2 April 2015 }} This added Serotec’s more than 15,000 antibodies, kits, and accessories to Bio-Rad’s portfolio of research and clinical diagnostic products.{{cite news|title=Bio-Rad Acquires AbD Serotec from MorphoSys|url=http://www.genengnews.com/gen-news-highlights/bio-rad-acquires-abd-serotec-from-morphosys/81247777/|publisher=Genetic Engineering & Biotechnology News|date=17 December 2012}}

In 2016, the company had direct distribution channels in over 35 countries outside the United States through subsidiaries whose focus is sales, customer service and product distribution. In some locations outside and inside these 35 countries, sales efforts were supplemented by distributors and agents.Bio-Rad Annual Report 2016

In 2017, Bio-Rad acquired RainDance Technologies, a droplet-based PCR systems manufacturer.{{cite web|url=https://www.genengnews.com/topics/omics/bio-rad-to-acquire-raindance-technologies/ |title=Bio-Rad to Acquire RainDance Technologies|date=16 January 2017|publisher=genengnews.com |accessdate=25 January 2022}}{{cite web|url=https://www.genomeweb.com/pcr/bio-rad-acquire-raindance-technologies |title=Bio-Rad to Acquire RainDance Technologies |date=16 January 2017 |publisher=genomeweb.com |accessdate=25 January 2022}}

In March 2021, Bio-Rad announced a partnership with Roche.{{cite web|url=https://www.genomeweb.com/molecular-diagnostics/bio-rad-laboratories-roche-enter-quality-control-partnership |title= Bio-Rad Laboratories, Roche Enter Quality Control Partnership |date= 8 March 2021 |publisher= genomeweb.com |accessdate=26 December 2021}}

=Vickers Instruments=

In 1989, Bio-Rad purchased the British instrument-making firm, Vickers (1828 - 1999), apart from their defense products, which were sold to British Aerospace. This company had been known until 1963 as Cooke, Troughton & Simms. Cooke, Troughton & Simms was formed in 1922 by the merging of T. Cooke & Sons, a York-based instrument maker founded in 1837 by the self-taught schoolmaster Thomas Cooke, and the London instrument-maker, Troughton & Simms founded in 1828 by Edward Troughton who began his apprenticeship in 1773.{{Cite web|url=https://www.york.ac.uk/borthwick/holdings/what-we-hold/businesses/vickers-instruments/|title=Vickers Instruments - Borthwick Institute for Archives, The University of York|website=www.york.ac.uk|access-date=2019-11-27}}

=Bioradiations=

Bioradiations is an online magazine created by Bio-Rad that offers researchers case studies, whitepapers, tips, techniques, and topics related to Bio-Rad products and services.{{cite web|url=https://www.bioradiations.com |title=Bioradiations |publisher=bioradiations .com |accessdate=21 January 2022}} Bioradiations began as a print magazine that was launched in 1965[http://www.biocompare.com/Life-Science-Promotions/41884-BioRadiations-The-Next-Generation/ BioCompare] and was printed until 2011 and replaced with the online publication.{{cite web|url= https://www.bioradiations.com/bioradiations-looks-back-50-years-as-bio-rads-life-science-resource |title=Bioradiations Looks Back |date=13 January 2015 |publisher=bioradiations .com |accessdate=21 January 2022}}

= FCPA bribery lawsuits =

From 2005 to 2010, Bio-Rad subsidiaries made bribes to foreign government officials, and made other payments intentionally ignoring the high likelihood of bribery. The bribes were estimated to have made $35.1 million profit for Bio-Rad, primarily from sales in Russia, Vietnam, and Thailand:{{Cite web |date=3 November 2014 |title=Cease and desist proceedings against Bio-Rad Laboratories, Inc. (Securities Exchange Act of 1934 Release No. 73496). |url=https://www.sec.gov/files/litigation/admin/2014/34-73496.pdf}}

In Russia, bribes were made as payments to foreign agents with phony Moscow addresses and off-shore bank accounts. These foreign agents aimed to win government contracts by influencing Russia's Ministry of Health.
In Vietnam, Bio-Rad's Singapore subsidiary regularly paid bribes to Vietnamese government officials. A regional sales manager raised concerns about this practice, and in response another employee proposed employing a middleman to pay the bribes instead.
In Thailand, Bio-Rad acquired Diamed Thailand with very little due diligence. Diamed Thailand was running an existing scheme to bribe government officials, which Bio-Rad's Asia Pacific General Manager later found out about in March 2008. They initiated an investigation, which confirmed the bribery was occurring, however did not instruct Diamed Thailand to stop the bribery and the payments continued until 2010.

In 2017, Bio-Rad paid $55 million to settle cases with the Department of Justice and the Securities and Exchange Commission for violating the Foreign Corrupt Practices Act (FCPA).{{Cite web |title=SEC.gov {{!}} SEC Charges California-Based Bio-Rad Laboratories With FCPA Violations |url=https://www.sec.gov/news/press-release/2014-245 |access-date=2023-12-21 |website=www.sec.gov}}{{Cite web |date=2014-11-03 |title=Office of Public Affairs {{!}} Bio-Rad Laboratories Resolves Foreign Corrupt Practices Act Investigation and Agrees to Pay $14.35 Million Penalty {{!}} United States Department of Justice |url=https://www.justice.gov/opa/pr/bio-rad-laboratories-resolves-foreign-corrupt-practices-act-investigation-and-agrees-pay-1435 |access-date=2023-12-21 |website=www.justice.gov |language=en}} The company was accused failing to prevent or detect bribes to foreign officials, and for falsifying its books to hide these bribes as legitimate expenses.

= Whistleblower retaliation lawsuit =

In 2013, Bio-Rad's general counsel of 25 years, Sanford Wadler, followed internal whistleblowing procedures by reporting suspected bribery to Bio-Rad's audit committee, believing Bio-Rad had falsified books and records. The company fired him for making this report, which the courts found to amount to California common law wrongful discharge in violation of public policy.

In 2017, a federal jury awarded Wadler with a $10.9 million settlement.{{Cite web |date=10 February 2017 |title=Fired Bio-Rad General Counsel Wins $10.9 Million in FCPA Whistleblower-Retaliation Case |url=https://buckleyfirm.com/blog/2017-02-10/fired-bio-rad-general-counsel-wins-109-million-fcpa-whistleblower-retaliation-case}} This was appealed by Bio-Rad, and in 2019 the US appeals court reduced this to $7.96 million, plus $3.5 million in attorneys' fees and costs.{{Cite web |last=Zuckerman |first=Jason |date=26 February 2019 |title=Bio-Rad Whistleblower Retains Most of his Record Whistleblower Retaliation Verdict on Appeal |url=https://www.natlawreview.com/article/bio-rad-whistleblower-retains-most-his-record-whistleblower-retaliation-verdict}}